Table 2 STING agonists involving in clinical development
From: Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy
Agents | molecular types | Route | With or without combinational agents | Targeting cancers | Phase | Clinical Trial NCT Code |
|---|---|---|---|---|---|---|
ADU-S100 /MIW815 | CDN analog | IT | alone or + Ipilimumab | Advanced/​metastatic solid tumors or lymphomas | Phase 1 | NCT02675439 |
|  |  | IT | +PDR001 | Advanced/​metastatic solid tumors or lymphomas | Phase 1/1b | NCT03172936 |
| Â | Â | IT | +Pembrolizumab | HNSCC | Phase 2 | NCT03937141 |
BMS-986,301 | CDN analog | IV/IT/ IM | Alone or+ Nivolumab and Ipilimumab | Advanced solid tumors | Phase 1 | NCT03956680 |
BI-1,387,446 | CDN analog | IT | Alone or + Ezabenlimab | Advanced/​metastatic solid tumors | Phase 1 | NCT04147234 |
IMSA-101 | CDN analog | IT | Alone or + ICI/+IO | Advanced solid tumors or lymphomas | Phase 1/2 | NCT04020185 |
| Â | Â | IT | +PULSAR, Pembrolizumab and Nivolumab | NSCLC and RCC | Phase 2 | NCT05846646 |
| Â | Â | IT | +PULSAR, Pembrolizumab and Nivolumab | Oligoprogressive solid tumors | Phase 2 | NCT05846659 |
MK-1454 | CDN analog | IT | + Alone or Pembrolizumab | Advanced/​metastatic solid tumors or lymphomas | Phase 1 | NCT03010176 |
| Â | Â | IT | +Pembrolizumab | Metastatic or unresectable, recurrent HNSCC | Phase 2 | NCT04220866 |
SB11285 | CDN analog | IV | Alone or + Atezolizumab | Advanced solid tumors | Phase 1 | NCT04096638 |
TAK-676 | CDN analog | IV | + Pembrolizumab | NSCLC, TNBC and HNSCC | Phase 1 | NCT04879849 |
IV | Alone or + Pembrolizumab | Advanced/​metastatic solid tumors | Phase 1 | NCT04420884 | ||
E7766 | non-CDN molecule | IT | Alone | NMIBC | Phase 1/1b | NCT04109092 |
|  |  | IT | Alone | Advanced/​metastatic solid tumors or lymphomas | Phase 1/1b | NCT04144140 |
GSK3745417 | non-CDN molecule | IV | Alone | AML and HR-MDS | Phase 1 | NCT05424380 |
|  |  | IV | Alone or + Dostarlimab | Advanced solid tumors | Phase 1 | NCT03843359 |
HG-381 | non-CDN molecule | IV | Alone | Advanced solid tumors | Phase 1 | NCT04998422 |
KL340399 | non-CDN molecule | IT | Alone | Advanced solid tumors | Phase 1 | NCT05549804 |
SNX281 | non-CDN molecule | IV | Alone or + Pembrolizumab | Advanced solid tumors or lymphomas | Phase 1 | NCT04609579 |
TAK-500 | antibody drug conjugate | IV | Alone or + Pembrolizumab | Advanced/​metastatic solid tumors | Phase 1/2 | NCT05070247 |
SYNB1891 | Engineered bacteria vectors | IT | Alone or + Atezolizumab | Advanced/​metastatic solid tumors or lymphomas | Phase 1 | NCT04167137 |